Drugs / KN713
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06012708 | Sep 2023 → Nov 2024 | cancer | New Cancer Cure-Bio Co.,Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07114861 | Dec 2025 → Sep 2028 expected | pancreatic ductal adenocarcinoma | New Cancer Cure-Bio Co.,Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN713 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06012708 ↗ |